Gabapentin
Test Mnemonic
GABA
CPT Codes
- 80171 - QTY (1)
LOINC ®
9738-6
Aliases
- Gabarone
- Neurontin
Performing Laboratory
ARUP
Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Serum | No additive (Red) | Refrigerated | Draw specimen within one hour prior to next dose. Do not use serum separator tubes. Separate serum from cells within 2 hours of collection and aliquot into standard transport tube. |
Alternate Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 1 mL | Plasma | EDTA (Lavender) | Refrigerated | Draw specimen within one hour prior to next dose. Do not use plasma separator tubes. Separate plasma from cells within 2 hours of collection and aliquot into standard transport tube. |
Minimum Specimen Requirements
| Volume | Type | Container | Collect Temperature | Transport Temperature | Special Instructions |
|---|---|---|---|---|---|
| 0.2 mL |
Stability
| Environmental Condition | Description |
|---|---|
| Ambient | After separation from cells: 1 month |
| Refrigerated | After separation from cells: 1 month |
| Frozen | After separation from cells: 2 months |
Days Performed
Mon, Wed, Thu, Fri, Sat
Turnaround Time
2 - 8 days
Methodology
| Name | Description |
|---|---|
| Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |
Reference Range
| Gabapentin | |||||
|---|---|---|---|---|---|
| Sex | Age From | Age To | Type | Range | Range Unit |
| Therapeutic Range: 2 - 20 ug/mL. Critical Range: Not well established. |
Special Info
Specimen should be collected within one hour prior to next dose - at steady state concentration. Unacceptable conditions include whole blood, gel separator tubes, light blue (citrate) or yellow (SPS or ACD solution). This test is New York DOH approved.
Clinical Info
Optimize drug therapy and monitor patient adherence. Pharmacokinetics of gabapentin vary widely among patients, particularly those with compromised renal function. Adverse effects may include somnolence, dizziness, ataxia, and fatigue.